Contepo is a drug owned by Meitheal Pharmaceuticals Inc. It is protected by 3 US drug patents filed in 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 30, 2039. Details of Contepo's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11541064 | Methods Of Identifying Dosing Regimens |
Jan, 2039
(12 years from now) | Active |
| US9345717 | Method For Improving Drug Treatments In Mammals |
Oct, 2034
(8 years from now) | Active |
| US10086006 | Method For Improving Drug Treatments In Mammals |
Oct, 2034
(8 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Contepo's patents.
Latest Legal Activities on Contepo's Patents
Given below is the list of recent legal activities going on the following patents of Contepo.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Change in Power of Attorney (May Include Associate POA) | 28 Apr, 2025 | US11541064 |
| Email Notification | 28 Apr, 2025 | US11541064 |
| Email Notification | 25 Apr, 2025 | US10086006 |
| Email Notification | 25 Apr, 2025 | US9345717 |
| Change in Power of Attorney (May Include Associate POA) | 25 Apr, 2025 | US10086006 |
| Change in Power of Attorney (May Include Associate POA) | 25 Apr, 2025 | US9345717 |
| Change in Power of Attorney (May Include Associate POA) | 27 Sep, 2024 | US9345717 |
| Email Notification | 27 Sep, 2024 | US10086006 |
| Email Notification | 27 Sep, 2024 | US11541064 |
| Change in Power of Attorney (May Include Associate POA) | 27 Sep, 2024 | US10086006 |
FDA has granted several exclusivities to Contepo. Till the time
these exclusivities
are active, no other company can market a generic or bioequivalent version of Contepo, regardless of the status of it's patents. These exclusivities hence play a crucial role in
delaying the generic
launch. Given below are details of the exclusivities granted to
Contepo.
Exclusivity Information
Contepo holds 2 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2033. Details of Contepo's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 22, 2028 |
| Generating Antibiotic Incentives Now(GAIN) | Oct 22, 2033 |
US patents provide insights into the exclusivity only within the United States, but
Contepo is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Contepo's family patents as well as insights into
ongoing legal events
on those patents.
Contepo's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Contepo's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jan 30, 2039 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Contepo Generics:
There are no approved generic versions for Contepo as of now.
About Contepo
Contepo is a drug owned by Meitheal Pharmaceuticals Inc. Contepo uses Fosfomycin Disodium as an active ingredient. Contepo was launched by Meitheal in 2025.
Approval Date:
Contepo was approved by FDA for market use on 22 October, 2025.
Active Ingredient:
Contepo uses Fosfomycin Disodium as the active ingredient. Check out other Drugs and Companies using Fosfomycin Disodium ingredient
Dosage:
Contepo is available in powder form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 6GM BASE/VIAL | POWDER | Prescription | INTRAVENOUS |